Bayer to acquire KaNDy Therapeutics in $875M women’s health play
KaNDy's lead product candidate, NT-814, is a non-hormonal treatment for symptoms of menopause. The drug completed Phase IIb testing and is slated to start Phase III testing next year.
These drug patents are expected to expire in 2020
According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. Two reports list 18 drugs as losing patent protection or exclusivity, though not all drugs listed here will necessarily face generic or biosimilar competition in 2020.
presented by
5 Major Trends Emerging in Healthcare Benefits in 2025
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
Bayer’s tumor-agnostic cancer drug gets European nod
Bayer said Monday that the European Medicines Agency had approved Vitrakvi for NTRK fusion-positive cancers. The drug won U.S. Food and Drug Administration accelerated approval in November.
Report: Swiss drugmaker Roche among several large firms targeted by hackers
According to an analysis, evidence pointed to a Chinese hacking group. German drugmaker Bayer was also targeted in April, apparently by Chinese hackers who used the same malware.
Lilly and Bayer’s LOXO-195 shows efficacy in TRK inhibitor-resistant tumors at AACR
Among 29 patients, the drug - designed for patients who become resistant to TRK inhibitors like Vitrakvi - showed a 34 percent response rate, according to Phase I data.
These are the biggest biopharma stories we covered in 2018
A roundup of some of the biggest trends and events in pharmaceuticals, biotechnology and diagnostics in 2018, including regulatory approvals, international trends, national policy and more.
presented by
How to Optimize Your Phlebotomy Setup for Efficient Patient Care
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
Loxo, Bayer’s Vitrakvi wins FDA approval. Now comes the hard part: finding patients
An oncologist compared NTRK fusion patients to a needle in a haystack, but had some clues of how to find them. Still, drugs like Vitrakvi call for genomic sequencing of all cancer patients, he said.
Past the pill and product: What do VCs want?
During a panel at MedCity INVEST, four experts addressed what VCs and potential acquirers are looking for in emerging companies.
Bayer’s special envoy to the world of digital health
Ahead of his participation in a breakout panel at MedCity INVEST in May, Bayer's U.S. head of digital innovation Dirk Schapeler discussed his role unique role finding and partnering with compatible digital companies around the world.
Bayer expanding its digital health accelerator program to San Francisco
The German life sciences company plans to bring its accelerator program for digital health startups to San Francisco. It's now available in Berlin, Moscow, and Shanghai among other places.
presented by
The Top 6 Best Analytics Tools for Health Care Revenue in 2025
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
CRISPR Therapeutics, Bayer launch $335M joint venture
The companies will develop new therapeutics targeted at blood disorders, blindness and congenital heart disease.
Morning Read: Essure in the crosshairs, meet Martin Shkreli before Daraprim
An interview with Martin Shkreli four years ago when he was heading up his first biotech company, Retrophin
As CGMs encroach, Bayer offloads diabetes unit to Panasonic for $1.13B
In a long-awaited deal, Bayer has sold its diabetes unit to Panasonic for $1.13 billion, thanks to growing competition from next-gen diabetes monitors.
Flagship Ventures teaming up with AstraZeneca, Nestlé and Bayer to speed up startup growth
Cambridge firm Flagship Ventures just announced a series of corporate partnerships to flesh out early stage funding for its portfolio companies and scale its in-house accelerator, VentureLabs. It just teamed up with AstraZeneca, Nestlé Health Science and Bayer CropScience, using each of the companies’ market knowledge – and pipeline for product development and commercialization. The trio also have […]
Unrest in Baltimore is affecting local healthcare, DaVita HealthCare Partners Inc. agrees to pay $495 million to settle a False Claims Act lawsuit (Morning Read)
TOP STORIES Unrest in Baltimore is affecting healthcare for many people in ways that are unfortunately under the radar compared to the constant news updates. DaVita HealthCare Partners Inc. has agreed to pay $495 million to settle a False Claims Act lawsuit that accused the Denver-based company of wasting significant amounts of iron and Vitamin […]